陕西肿瘤医学
陝西腫瘤醫學
협서종류의학
SHAANXI ONCOLOGY MEDICINE
2001年
1期
14-16,63
,共4页
甲状腺乳头状癌%表皮生长因子受体%淋巴结转移
甲狀腺乳頭狀癌%錶皮生長因子受體%淋巴結轉移
갑상선유두상암%표피생장인자수체%림파결전이
目的研究EGFR及其配体EGF与甲状腺乳头状癌淋巴结转移的关系。方法本实验采用免疫组化S-P法，检测了251例甲状腺乳头状癌表皮生长因子受体(EGFR)，分析了受体表达情况与淋巴转移间的关系。并检测了53例甲状腺乳头状癌患者血清及尿液中表皮生长因子(EGF)的水平。结果在甲状腺乳头状癌中，EGFR出现高水平表达，阳性率为66.9％，明显高于对照组。不同病理分型间，阳性率有所不同。包膜内型、腺内型和腺外型阳性率分别为29.4％、73.9％和71.3％，其差别有统计学意义。当出现淋巴结转移时，EGFR阳性率升高。N0转移组及N1组EGFR阳性率为88.7％，91.0％明显高于N0无转移组(19.5％)，有显著性差异。经相对危险度计算和线性趋势分析表明，随EGFR染色强度升高，转移风险升高，二者间呈线性关系。甲状腺乳头状癌患者血清及尿液中存在着高水平的EGF。甲状腺乳头状癌患者血清EGF水平为1.68±56μg/L，尿液中为37.2±10.8μg/L，均高于甲状腺腺瘤组和正常对照组。提示EGF与肿瘤的发生有密切关系。结论在N0期甲状腺乳头状癌病例中，EGFR阳性应高度考虑颈淋巴结转移，从而为临床选择治疗方案提供参考。
目的研究EGFR及其配體EGF與甲狀腺乳頭狀癌淋巴結轉移的關繫。方法本實驗採用免疫組化S-P法，檢測瞭251例甲狀腺乳頭狀癌錶皮生長因子受體(EGFR)，分析瞭受體錶達情況與淋巴轉移間的關繫。併檢測瞭53例甲狀腺乳頭狀癌患者血清及尿液中錶皮生長因子(EGF)的水平。結果在甲狀腺乳頭狀癌中，EGFR齣現高水平錶達，暘性率為66.9％，明顯高于對照組。不同病理分型間，暘性率有所不同。包膜內型、腺內型和腺外型暘性率分彆為29.4％、73.9％和71.3％，其差彆有統計學意義。噹齣現淋巴結轉移時，EGFR暘性率升高。N0轉移組及N1組EGFR暘性率為88.7％，91.0％明顯高于N0無轉移組(19.5％)，有顯著性差異。經相對危險度計算和線性趨勢分析錶明，隨EGFR染色彊度升高，轉移風險升高，二者間呈線性關繫。甲狀腺乳頭狀癌患者血清及尿液中存在著高水平的EGF。甲狀腺乳頭狀癌患者血清EGF水平為1.68±56μg/L，尿液中為37.2±10.8μg/L，均高于甲狀腺腺瘤組和正常對照組。提示EGF與腫瘤的髮生有密切關繫。結論在N0期甲狀腺乳頭狀癌病例中，EGFR暘性應高度攷慮頸淋巴結轉移，從而為臨床選擇治療方案提供參攷。
목적연구EGFR급기배체EGF여갑상선유두상암림파결전이적관계。방법본실험채용면역조화S-P법，검측료251례갑상선유두상암표피생장인자수체(EGFR)，분석료수체표체정황여림파전이간적관계。병검측료53례갑상선유두상암환자혈청급뇨액중표피생장인자(EGF)적수평。결과재갑상선유두상암중，EGFR출현고수평표체，양성솔위66.9％，명현고우대조조。불동병리분형간，양성솔유소불동。포막내형、선내형화선외형양성솔분별위29.4％、73.9％화71.3％，기차별유통계학의의。당출현림파결전이시，EGFR양성솔승고。N0전이조급N1조EGFR양성솔위88.7％，91.0％명현고우N0무전이조(19.5％)，유현저성차이。경상대위험도계산화선성추세분석표명，수EGFR염색강도승고，전이풍험승고，이자간정선성관계。갑상선유두상암환자혈청급뇨액중존재착고수평적EGF。갑상선유두상암환자혈청EGF수평위1.68±56μg/L，뇨액중위37.2±10.8μg/L，균고우갑상선선류조화정상대조조。제시EGF여종류적발생유밀절관계。결론재N0기갑상선유두상암병례중，EGFR양성응고도고필경림파결전이，종이위림상선택치료방안제공삼고。
Objective To study the relationship between expression of EGFR and lymphatic metastasis in Papillary thyroid carcinoma. Methods We retrospectively studied 251 cases of papillary thyroid carcinoma EGFR were measured by an immuno- histochemical assay. And EGF level of serum and urine were detected by immunoradiometric assay in 53 cases of papillary thyrlid carcinoma. Results 66.9％ cases present overexpression of EGFR. It's higher than that of control group(p＜0.01). And expression of EGFR were increased in patients with lymphatic metastases. in N0 non- metastasis group, the positive rate was lower than that of N0 metastasis and N1 group (p＜0.01). O. R showed a significant association between the risk of metastasis and expression of EGFR. Comparing with control group,patients had higher level of EGF in both serum and urine. It indicated that EGF had association with carcinogenesis. Conclusion In No papillary thyroid carcinoma patients,it would be the high-risk group of lymphatic metastasis that had high expression of EGFR.
